David Feltquate - Aug 1, 2024 Form 4 Insider Report for iTeos Therapeutics, Inc. (ITOS)

Role
Chief Medical Officer
Signature
/s/ Adi Osovsky, as Attorney-in-Fact
Stock symbol
ITOS
Transactions as of
Aug 1, 2024
Transactions value $
$0
Form type
4
Date filed
8/5/2024, 07:19 AM
Previous filing
Aug 5, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ITOS Stock Option (Right to Buy) Award $0 +350K $0.00 350K Aug 1, 2024 Common Stock 350K $17.46 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This stock option will vest over 4 years, with 25% of the stock option vesting on August 1, 2025, and thereafter in equal monthly installments over the next 36 months, subject to the Reporting Person's continued service through the applicable vesting date.